According to the report published by AstraZeneca in May 2024, company estimated the epidemiology Hypophosphatasia (HPP) affects fewer than 6,000 patients in the U.S., underlining its status as a rare disease. This rarity presents a significant driver in the hypophosphatasia market, characterized by a substantial unmet medical need and potential for focused therapeutic development.
According to the article published by the NORD – National Organization for Rare Disorders, Inc., in February 2021 Hypophosphatasia (HPP) is most frequently observed in the Mennonite population in Canada due to genetic factors such as a higher occurrence of specific mutations within this genetically homogenous group. In Japan, the higher prevalence can be attributed to both genetic predisposition and possibly more effective screening and diagnostic practices, leading to better identification and reporting of HPP cases.
